Vyleesi weight loss claims are misleading: bremelanotide is FDA-approved for low libido in premenopausal women, not for weight loss. Here's what to know.
Vyleesi (bremelanotide) is not a weight loss medication, and the FDA has never approved it for that purpose. The drug is approved only to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. Any post, video, or product promising Vyleesi weight loss results is overstating what the evidence actually shows.
What Vyleesi Is Actually Approved For
Vyleesi is a subcutaneous injection of bremelanotide, a synthetic peptide that activates melanocortin receptors in the brain. The FDA approved it in June 2019 for acquired, generalized HSDD in premenopausal women.
The dosing is narrow and tightly limited:
- 1.75 mg injected under the skin of the abdomen or thigh
- Take at least 45 minutes before anticipated sexual activity
- No more than one dose in 24 hours
- No more than eight doses in a month
Vyleesi is not approved for men, for postmenopausal women, or for any weight-related condition. It is dispensed through certified pharmacies and carries a boxed warning about transient blood pressure increases.
Why "Vyleesi Weight Loss" Shows Up in Searches
The confusion traces back to the melanocortin system. A different drug in the same receptor family, setmelanotide (brand name Imcivree), is FDA-approved for weight management in people with specific rare genetic forms of obesity.
It is easy to see why someone would assume the family resemblance means bremelanotide also reduces body fat. It does not work that way. Vyleesi and setmelanotide are different molecules with different receptor activity, different doses, and different durations of action.
A second source of the rumor is melanotan II, an unapproved tanning peptide that some users claim curbs appetite. Melanotan II is not Vyleesi, and it is not legally sold for human use in the United States.
Nausea is part of the story too. Roughly 40% of women in the trials reported nausea, and a queasy stomach is sometimes mistaken for a weight-loss effect. That is a side effect, not a treatment mechanism, and it fades.
| Medication | FDA-approved use | Approved for weight loss? |
|---|---|---|
| Vyleesi (bremelanotide) | HSDD in premenopausal women | No |
| Imcivree (setmelanotide) | Obesity caused by specific genetic conditions | Yes, only for confirmed genetic diagnoses |
| Wegovy (semaglutide) | Chronic weight management | Yes |
| Zepbound (tirzepatide) | Chronic weight management | Yes |
What the Clinical Trials Actually Measured
The RECONNECT program enrolled roughly 1,200 premenopausal women with HSDD and ran for 24 weeks. The endpoints were sexual desire and distress related to low desire, not body weight.
No published trial has shown that bremelanotide produces meaningful or lasting weight loss. Weight change was not reported as a benefit, and there is no long-term data on weight outcomes with this drug.
Known side effects include:
- Nausea, flushing, and headache
- Injection-site reactions such as pain, bruising, or itching
- Transient increases in blood pressure after a dose
- Focal hyperpigmentation of the skin, gums, or nails with repeated use
Vyleesi is contraindicated in women with uncontrolled hypertension or known cardiovascular disease, and it should not be taken with oral naltrexone. Anyone considering it should review their cardiovascular history with a licensed healthcare professional first.
Other Peptides People Search For Alongside Vyleesi
Weight-related peptide searches rarely stop at one compound. Questions such as does bpc-157 help with weight loss come up constantly, even though human data on body composition remain thin.
The same is true for does kpv help with weight loss and similar peptides marketed for gut or inflammation support. These are research chemicals, not approved therapies, and products sold online are not guaranteed to contain what the label claims.
Compounds described as aod 9604 for weight loss are a fragment of human growth hormone, and they are frequently promoted on gray-market sites without FDA approval for any indication. Ongoing interest in cjc-1295 weight loss and cjc 1295 ipamorelin for weight loss follows the same pattern: early-stage research, aggressive marketing, and very little controlled human evidence.
None of these peptides is a substitute for a supervised weight-management plan. Injecting unregulated peptides carries real risks, including contamination, inaccurate dosing, and unknown long-term effects.
What Has Better Evidence for Weight Loss
If weight loss is the goal, the strongest evidence supports FDA-approved medications such as semaglutide and tirzepatide, along with older options like phentermine or orlistat. Each is paired with nutrition and activity changes and monitored by a clinician.
Those drugs have large trials behind them, defined dosing, and clear monitoring plans. They also carry their own side effects, which is exactly why they are prescribed and supervised rather than purchased from a website.
Using Vyleesi off-label for weight loss would mean paying out of pocket for a drug with no demonstrated weight benefit, plus cardiovascular risks and a boxed warning. That trade-off is difficult to justify.
Bottom Line on Vyleesi and Weight Loss
- Vyleesi is FDA-approved for HSDD in premenopausal women and for nothing else.
- No clinical trial has demonstrated that bremelanotide causes meaningful weight loss.
- Nausea on Vyleesi is a side effect, not a weight-loss strategy.
- FDA-approved weight-loss medications such as semaglutide and tirzepatide have far stronger supporting evidence.
- Talk with a healthcare professional before using any prescription drug or research peptide for weight loss.
Frequently Asked Questions
Does Vyleesi cause weight loss?
No. In the trials that led to its approval, bremelanotide was tested for low sexual desire, not for weight loss, and no meaningful weight change was reported. Some women feel nauseated after a dose, which can briefly blunt appetite, but that is a side effect rather than a weight-loss effect.
Can a doctor prescribe Vyleesi for weight loss?
Vyleesi is FDA-approved only for hypoactive sexual desire disorder in premenopausal women, so prescribing it for weight loss would be off-label. Most insurers will not cover it for that purpose, and the boxed warning about blood pressure increases makes off-label use for weight loss risky.
How much weight can you lose on Vyleesi?
There is no reliable number, because no study has shown a weight-loss benefit from bremelanotide. Vyleesi is not a substitute for semaglutide, tirzepatide, or other medications approved for chronic weight management.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.